The global pharmaceutical industry has marked impressive growth over the past couple of decades, with the total revenues worldwide breaking the threshold of 1 trillion US dollars for the first time in 2014 and continuing their steep progress ever since. While China is growing fast, the US and Europe are still the key players with leading pharmaceutical companies dominating the market.
Given the size but also the significance – for the human life – of the industry, maybe it does not come as a surprise to hear that there are tens of thousands of drugs that never make it to the shelf – only a couple of dozens of new drugs receive approval for market every year. However, the following figures cannot but leave us aghast:
Given the length of this journey, two things are readily deduced:
With some of the biggest pharma companies investing up to 20% or even more of their revenues in R&D, contract research organizations (CROs) have emerged to support the industry, providing contract services for the whole spectrum of processes, from clinical research strategy and clinical trial design to regulatory submission, commercialization and post-market surveillance, and aim to reduce costs and shorten time to market. Except for activities targeted to the domestic market, CROs also support the pharma companies in their quest to pursue licensing approval in different countries and thus enter new markets. One of the additional tasks they undertake as part of the latter is the translation/localization/adaptation of the relevant documentation, which can range from PILs, SPCs, CRFs, ICFs, PROMs, SUSARs to QoL scales, protocols, labeling etc.
There are however pharma companies which choose to run translation projects on their side, despite of whether they outsource other services to a CRO or not. And although having the budget to outsource may be considered an asset in some companies, other companies may own all or parts of the process, including content localization, and view this as a luxury.
There is no right or wrong option here, as the scale of the research and the set-up of the company plays a huge role in the option to be selected, and both options have two sides which weigh differently depending on the setting, and this is how the localization business and translation agencies find themselves working for both pharma companies directly and for CROs. While one might think that process-wise the differences between the two setups are from negligent to minimal, when it comes to translation, it seems that price, speed and occasionally quality levels are the aspects that are affected more when outsourced to a CRO as part of the overall package of managed services, and let’s see why.
CROs have a rich offering for the whole journey of a drug, and some even have internal localization departments or managers, still the translation task per se is outsourced to multilingual translation companies who have the relevant capacity and resources, often themselves outsourcing it to smaller specialized in Life Sciences companies or teams of linguists. It is therefore clear why this is usually pricier and lengthier, but if it saves you time and resources otherwise, and the post-translation steps in the process are handled by your CRO and are still on schedule, it is probably fine, isn’t it?
Quality in translation should not be a process, it should be a mindset fully integrated in the entire production model, starting from the resourcing strategy, the selection and evaluation criteria, to the project management philosophy, identifying and making available all relevant reference material, such as appropriate templates and proper terminology resources and coding conventions (eg. MedRA, WHOART, COSTART) and effectively handling the query process amongst many languages, and all the way to the final deliverables, applying automated and manual quality checks along the way. And of course, the definition of quality and hence its measurement and assessment varies depending on the purpose. When it comes to CROs, quality is indeed of paramount importance, but quality processes pertain primarily to their core services. However, this is why they outsource this to the experts, translation agencies! And this is the a-ha moment!
If you are a pharmaceutical company using a CRO for part of your drug development journey, and translation is included in this offering, good for you. You have a knowledgeable partner to support you throughout this challenging process. The same goes if you are considering to on-board one. Investing in know-how and experience, assuming you have the budget, could be a step towards faster commercialization. In this case what you may want to know about your CRO regarding the translation of your documentation is:
If you are a pharmaceutical company which prefers to own the localization stage – whether you are using a CRO for other services or not – then here are some thoughts you might find useful:
Although, it’s good to have your process set, there may be points you are uncertain of. In this case, it’s better to turn to your translation & localization partner for consult, as they may be able to share best practices from other set-ups and workflows they may be working on or even willing to set up a new customized process that would meet your particular needs.
While there is no right or wrong option when it comes to forming your company’s translation strategy within the pharma industry, it is important to be aware of the variations between setups. This way you can better evaluate which one best fits your given workflow, taking into account your priorities, capacities and limitations.
If you want more information, you can get in touch with us; we are always glad to help!
CRO Contract Research Organization
MHRA Medicines and Healthcare products Regulatory Agency
EMA European Medicines Agency
FDA Food and Drug Administration
ICSR Individual Case Safety Report
SUSAR Suspected Unexpected Serious Adverse Reaction
CRF Case Report Form
ICF Informed Consent Form
PROMs Patient Reported Outcome Measures
QoL Quality of Life
PIL Patient Information Leaflet
SPC Summaries of Product Characteristics
As we wrap up 2023, let's rewind and revisit our ten most popular blog posts…
https://www.youtube.com/watch?v=204nn9QPJcI The linguistic landscape of China is as vast and diverse as the country itself,…
https://youtu.be/j7SEBtoEASQ The holiday season is a time of joy and celebration, and one of the…
Your globalization and market expansion strategy calls for a very targeted localization approach, even in…
Listen to this article now: https://youtu.be/O7eDRmackvI Language is a powerful tool that reflects and shapes…
Listen to this article now: https://youtu.be/u1WCW4XVXS0 Embarking on global expansion is a strategic leap requiring…